10:55:25Philippines

Evommune, Inc. (EVMN)

NYSE

Key stats Fiscal year 2025

Income statement

Revenue
13,000,000 85.7%
Net income
-68,870,000
Operating income
-81,071,000
Earnings per share
-11.22
R&D expense
74,042,000

Growth and profitability

Operating margin
-623.62
Net margin
-529.77
Return on equity
-33.50
Return on assets
-30.62
Free cash flow margin
-589.82

Balance sheet

Total assets
224,946,000
Total liabilities
19,380,000
Shareholders' equity
205,566,000
Cash and equivalents
44,063,000
Current ratio
8.57

Cash flow and ratios

Operating cash flow
-76,441,000
Free cash flow
-76,676,000

Shareholder returns

Shares outstanding
41,349,860
Book value per share
4.97
Revenue and net income
From revenue to profit 2025
Debt, free cash flow and cash
Earnings per share

Company information

Headquarters
Palo Alto, CA
Exchange
NYSE
Fiscal year end
12-31
Industry (SEC)
Pharmaceutical Preparations

Fiscal year end: · Source: SEC EDGAR

Evommune, Inc. trades on NYSE under the ticker symbol EVMN. This page brings together its price chart, company profile, key financial figures and technical indicators.

Company profile

Technical analysis